Noninvasive detection of cardiac repair after acute myocardial infarction in rats by 111in Fab fragment of monoclonal antibody specific for Tenascin-C

International Heart Journal

Volumn 49, Issue 4, 2008, Pages 481-492

  Odaka, Kenichi ^a   Uehara, Tomoya ^b   Arano, Yasushi ^b   Adachi, Sayaka ^b   Tadokoro, Hiroyuki ^a   Yoshida, Katsuya ^a   Hasegawa, Hiroshi ^a   Imanaka Yoshida, Kyoko ^c   Yoshida, Toshimichi ^c   Hiroe, Michiaki ^d   Irie, Toshiaki ^e   Tanada, Shuji ^e   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b CHIBA UNIVERSITY   (Japan)

^c MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^e NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

Cardiac repair; Extracellular matrix; Fab fragment; Myocardial infarction; Single photon emission computed tomography; Tenascin C

Indexed keywords

IMMUNOGLOBULIN F(AB) FRAGMENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TENASCIN IN 111; UNCLASSIFIED DRUG; DIAGNOSTIC AGENT; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ARTICLE; AUTORADIOGRAPHY; CONTROLLED STUDY; HEART INFARCTION; HEART VENTRICLE REMODELING; IMAGE ENHANCEMENT; IMAGE QUALITY; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; NON INVASIVE MEASUREMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOACTIVITY; RAT; SHAM PROCEDURE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; COMPARATIVE STUDY; DISEASE COURSE; DISEASE MODEL; HOSPITALIZATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MALE; MYOCARDIAL INFARCTION; RATS; RATS, WISTAR; SEVERITY OF ILLNESS INDEX; TENASCIN; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VENTRICULAR REMODELING;

EID: 52149119134     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.49.481     Document Type: Article

References (31)

1. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 1990; 81: 1161-72.
2. Tyagi SC. Proteinases and myocardial extracellular matrix turnover. Mol Cell Biochem 1997; 168: 1-12.
3. Imanaka-Yoshida K, Hiroe M, Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Histopathol 2004; 19: 517-25.
4. Imanaka-Yoshida K, Hiroe M, Nishikawa T, et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 2001; 81: 1015-24.
5. Sato A, Aonuma K, Imanaka-Yoshida K, et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 2006; 47: 2319-25.
6. Chaulet H, Lin F, Guo J, et al. Sustained augmentation of cardiac alpha1A-adrenergic drive results in pathological remodeling with contractile dysfunction, progressive fibrosis and reactivation of matricellular protein genes. J Mol Cell Cardiol 2006; 40: 540-52.
7. Reynolds JC, Del Vecchio S, Sakahara H, et al. Anti-murine antibody response to mouse monoclonal antibodies: clinical findings and implications. Int J Rad Appl Instrum B 1989; 16: 121-5.
8. Seccamani E, Tattanelli M, Mariani M, Spranzi E, Scassellati GA, Siccardi AG. A simple qualitative determination of human antibodies to murine immunoglobulins (HAMA) in serum samples. Int J Rad Appl Instrum B 1989; 16: 167-70.
9. Saga Y, Yagi T, Ikawa Y, Sakakura T, Aizawa S. Mice develop normally without tenascin. Genes Dev 1992; 6: 1821-31.
10. Aukhil I, Slemp CC, Lightner VA, Nishimura K, Briscoe G, Erickson HP. Purification of hexabrachion (tenascin) from cell culture conditioned medium, and separation from a cell adhesion factor. Matrix 1990; 10: 98-111.
11. Imanaka-Yoshida K, Hiroe M, Yasutomi Y, et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002; 197: 388-94.
12. Cummins CH, Rutter EW Jr, Fordyce WA. A convenient synthesis of bifunctional chelating agents based on diethylenetriaminepentaacetic acid and their coordination chemistry with yttrium (III). Bioconjug Chem 1991; 2: 180-6.
13. Arano Y, Mukai T, Uezono T, et al. A biological method to evaluate bifunctional chelating agents to label antibodies with metallic radionuclides. J Nucl Med 1994; 35: 890-8.
14. Arano Y, Uezono T, Akizawa H, et al. Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative. J Med Chem 1996; 39: 3451-60.
15. Arano Y, Wakisaka K, Mukai T, et al. Stability of a metabolizable ester bond in radioimmunoconjugates. Nucl Med Biol 1996; 23: 129-36.
16. Sato M, Toyozaki T, Odaka K, et al. Detection of experimental autoimmune myocarditis in rats by 111In monoclonal antibody specific for tenascin-C. Circulation 2002; 106: 1397-02.
17. Khaw BA, Petrov A, Narula J. Complementary roles of antibody affinity and specificity for in vivo diagnostic cardiovascular targeting: how specific is antimyosin for irreversible myocardial damage? J Nucl Cardiol 1999; 6: 316-23.
18. Tanaka R, Nakamura T. Time course evaluation of myocardial perfusion after reperfusion therapy by 99mTctetrofosmin SPECT in patients with acute myocardial infarction. J Nucl Med 2001; 42: 1351-8.
19. Puig M, Ballester M, Matias-Guiu X, et al. Burden of myocardial damage in cardiac allograft rejection: scintigraphic evidence of myocardial injury and histologic evidence of myocyte necrosis and apoptosis. J Nucl Cardiol 2000; 7: 132-9.
20. Sarda L, Colin P, Boccara F, et al. Myocarditis in patients with clinical presentation of myocardial infarction and normal coronary angiograms. J Am Coll Cardiol 2001; 37: 786-92.
21. Hofstra L, Liem IH, Dumont EA, et al. Visualization of cell death in vivo in patients with acute myocardial infarction. Lancet 2000; 356: 209-12.
22. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med 2001; 7: 1347-52.
23. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation 2005; 112: 3157-67.
24. Willems IE, Arends JW, Daemen MJ. Tenascin and fibronectin expression in healing human myocardial scars. J Pathol 1996; 179: 321-5.
25. Frangogiannis NG, Shimoni S, Chang SM, et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol 2002; 39: 1468-74.
26. Wallner K, Li C, Shah PK, et al. Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 1999; 99: 1284-9.
27. Imanaka-Yoshida K, Matsuura R, Isaka N, Nakano T, Sakakura T, Yoshida T. Serial extracellular matrix changes in neointimal lesions of human coronary artery after percutaneous transluminal coronary angioplasty: clinical significance of early tenascin-C expression. Virchows Arch 2001; 439: 185-90.
28. Kalembeyi I, Inada H, Nishiura R, Imanaka-Yoshida K, Sakakura T, Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor beta1. Int J Cancer 2003; 105: 53-60.
29. Tamaoki M, Imanaka-Yoshida K, Yokoyama K, et al. Tenascin-C regulates recruitment of myofibroblasts during tissue repair after myocardial injury. Am J Pathol 2005; 167: 71-80.
30. Toma N, Imanaka-Yoshida K, Takeuchi T, et al. Tenascin-C-coated platinum coils for acceleration of organization of cavities and reduction of lumen size in a rat aneurysm model. J Neurosurg 2005; 103: 681-6.
31. McLendon RE, Akabani G, Friedman HS, et al. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nucl Med Biol 2007; 34: 405-13.